Cancer cells possess a remarkable quality called plasticity. This means they can change their form. This ability helps them survive and spread. Cancer cells act like young cells. They can adapt to ...

Risk of progression differs in high risk and low risk cases when surgery is omitted Ductal carcinoma in situ (DCIS) is a non-obligate precursor lesion of invasive breast cancer. Since the ...

Have you ever heard about a cancer that is "in situ"? There's a reason why it's called that -- and why it's the kind of ...

Women diagnosed with DCIS face a threefold higher risk of breast cancer mortality. Learn the warning signs, treatment options and monitoring strategies.

Results In the longitudinal cohorts, the only statistically significant associations with time to non-invasive DCIS recurrence were the combination of treatment (lumpectomy only vs mastectomy or ...

The hormone therapy tamoxifen can keep cancer from recurring in women with DCIS Tamoxifen following lumpectomy reduced risk of recurrence 44% to 51% Tamoxifen blocks estrogen receptors in cancer ...

Most often the decision to treat DCIS with either lumpectomy or mastectomy is based on the results from mammography alone. However, a previous trial showed that MRI sensitivity for detection of DCIS ...

Women who took tamoxifen after undergoing a lumpectomy to remove ductal carcinoma in situ (DCIS) were 44% to 51% less likely to have their cancer return in that breast, researchers reported last ...

What This Means For You Women with low-risk DCIS should talk to their doctor about taking tamoxifen after they undergo lumpectomy for their cancer.

DCIS, known as stage 0 breast cancer, affect the cells lining the milk ducts but has not spread outside the breast.